The Lead Episode 8: A Discussion of Individualized Family Screening for Arrhythmogenic Right Ventricular Cardiomyopathy

Description

Andrew D. Krahn, MD, FHRS discusses this article with guests Jason D. Roberts, MD and Julia Cadrin-Tourigny, MD, PhD, CCDS. Clinical guidelines recommend regular screening for arrhythmogenic right ventricular cardiomyopathy (ARVC) to monitor at-risk relatives, resulting in a significant burden on clinical resources. Prioritizing relatives on their probability of developing definite ARVC may provide more efficient patient care.

Learning Objectives

The aim of this study was to determine the predictors and probability of ARVC development over time among at-risk relatives.

Article Authors and Podcast Contributors

Article Authors
Steven A. Muller, Alessio Gasperetti, Laurens P. Bosman, Amand F. Schmidt, Annette F. Baas, Ahmad S. Amin, Arjan C. Houweling,Arthur A.M. Wilde, Paolo Compagnucci, Mattia Targetti, Michela Casella, Leonardo Calò, Claudio Tondo, Pim van der Harst, Folkert W. Asselbergs, J. Peter van Tintelen, Marish I.F.J. Oerlemans, Anneline S.J.M. te Riele

Podcast Contributors
Andrew D. Krahn, MD, FHRS of University of British Columbia
Jason D. Roberts, MD of McMaster University
Julia Cadrin-Tourigny, MD, PhD, CCDS of Montreal Heart Institute

Disclosure Policy

All relevant financial relationships have been mitigated.

Host Disclosure(s):
A. Krahn: Honoraria/Speaking/Consulting Fee: Medtronic, Inc

Contributor Disclosure(s):
J. Roberts: Honoraria/Speaking/Consulting Fee: Ionis Pharmaceuticals
J. Cadrin-Tourigny: Honoraria/Speaking/Consulting Fee: BMS/Pfizer Alliance, Bayer Healthcare Pharmaceuticals, Tenaya Therapeutics

Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):
J. Glenn: No relevant financial relationships with ineligible companies to disclose.
S. Sailor: No relevant financial relationships with ineligible companies to disclose.

Summary


Availability:	On-Demand


Cost:	FREE


Credit Offered:	No Credit Offered

Recommended

The Lead Episode 70: A Discussion of the 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation

Multiple Credits

FREE

The Lead Episode 66: Class 1C Antiarrhythmics for Premature Ventricular Complex Suppression in Nonischemic Cardiomyopathy with Implantable Cardioverter-Defibrillators

Multiple Credits

FREE

(1)

Heart Rhythm 2024 On Demand - Clinical Electrophysiology

Multiple Credits

$299.00 - $399.00

(1)

Heart Rhythm 2024 On Demand - Ablation

Multiple Credits

$249.00 - $349.00

Heart Rhythm 2024 On Demand – Various Sessions

Multiple Credits

$249.00 - $349.00

(1)

The Lead Episode 57: A Discussion of EsophAguS Deviation During RadiofrequencY Ablation of Atrial Fibrillation: The EASY AF Trial

Multiple Credits

FREE

(1)

The Lead Episode 50: New-onset atrial fibrillation prediction: the HARMS2-AF risk score

Multiple Credits

FREE

Core Concepts in Remote Monitoring 2023 Module 1: The Current State of Remote Monitoring in EP

Multiple Credits

$99.00 - $125.00

(7)

The Beat Webinar Series - Episode 5 - A Seat at the Table: Understanding CPT® and RUC (On Demand)

Multiple Credits

FREE

(4)

The Beat Webinar Series - Episode 1 - Management of Electrical Storm

Multiple Credits

$25.00 - $50.00